Zobrazeno 1 - 10
of 14
pro vyhledávání: '"H T Claude Chan"'
Autor:
C Ian Mockridge, H T Claude Chan, Mark S Cragg, Jinny Kim, Tatyana Inzhelevskaya, Jane E Willoughby, Julia Moreno-Vicente, Martin C Taylor, Steven G Booth, Vikki L English, Emily L Williams, Christine A Penfold, Juliet C Gray, Stephen A Beers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/0d95105e612946869ce83db4c68db191
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Immune compromised mice are increasingly used for the preclinical development of monoclonal antibodies (mAb). Most common are non-obese diabetic (NOD) severe combined immunodeficient (SCID) and their derivatives such as NOD SCID interleuki
Externí odkaz:
https://doaj.org/article/8f12a34eedcd4356b830ac47f7795691
Autor:
Xiaojie Yu, Christian M. Orr, H. T. Claude Chan, Sonya James, Christine A. Penfold, Jinny Kim, Tatyana Inzhelevskaya, C. Ian Mockridge, Kerry L. Cox, Jonathan W. Essex, Ivo Tews, Martin J. Glennie, Mark S. Cragg
Antibody responses during infection and vaccination typically undergo affinity maturation to achieve high-affinity binding for efficient neutralization of pathogens1,2. Similarly, high affinity is routinely the goal for therapeutic antibody generatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3413a611d84ceac2eb9f01db8758a17
https://eprints.soton.ac.uk/475620/
https://eprints.soton.ac.uk/475620/
Autor:
Julia Moreno-Vicente, Jane E Willoughby, Martin C Taylor, Steven G Booth, Vikki L English, Emily L Williams, Christine A Penfold, C Ian Mockridge, Tatyana Inzhelevskaya, Jinny Kim, H T Claude Chan, Mark S Cragg, Juliet C Gray, Stephen A Beers
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundDespite extensive clinical use, the mechanisms that lead to therapeutic resistance to anti-programmed cell-death (PD)-1 monoclonal antibodies (mAbs) remain elusive. Here, we sought to determine how interactions between the Fc region of anti
Autor:
Marcus A Widdess, H. T. Claude Chan, Christine A Penfold, C Ian Mockridge, Tatyana Inzhelevskaya, Hannah J Metcalfe, Mark S Cragg, Aymen Al-Shamkhani
Publikováno v:
Cancer Immunology Research. 10:A26-A26
Immunostimulatory antibodies targeting co-stimulatory TNFRSF members have shown promise in pre-clinical cancer models, but this has not translated into clinical success, primarily due to lack of efficacy. Oligomerisation of the co-stimulatory molecul
Autor:
Franziska, Heckel, Anna H, Turaj, Hayden, Fisher, H T Claude, Chan, Michael J E, Marshall, Osman, Dadas, Christine A, Penfold, Tatyana, Inzhelevskaya, C Ian, Mockridge, Diego, Alvarado, Ivo, Tews, Tibor, Keler, Stephen A, Beers, Mark S, Cragg, Sean H, Lim
Publikováno v:
Communications biology. 5(1)
Agonistic CD27 monoclonal antibodies (mAb) have demonstrated impressive anti-tumour efficacy in multiple preclinical models but modest clinical responses. This might reflect current reagents delivering suboptimal CD27 agonism. Here, using a novel pan
Autor:
Xiaojie, Yu, H T Claude, Chan, Christian M, Orr, Osman, Dadas, Steven G, Booth, Lekh N, Dahal, Christine A, Penfold, Lyn, O'Brien, C Ian, Mockridge, Ruth R, French, Patrick, Duriez, Leon R, Douglas, Arwen R, Pearson, Mark S, Cragg, Ivo, Tews, Martin J, Glennie, Ann L, White
Publikováno v:
Cancer cell. 33(4)
Anti-CD40 monoclonal antibodies (mAbs) that promote or inhibit receptor function hold promise as therapeutics for cancer and autoimmunity. Rules governing their diverse range of functions, however, are lacking. Here we determined characteristics of n
Autor:
Ann L, White, H T Claude, Chan, Ruth R, French, Jane, Willoughby, C Ian, Mockridge, Ali, Roghanian, Christine A, Penfold, Steven G, Booth, Ali, Dodhy, Marta E, Polak, Elizabeth A, Potter, Michael R, Ardern-Jones, J Sjef, Verbeek, Peter W M, Johnson, Aymen, Al-Shamkhani, Mark S, Cragg, Stephen A, Beers, Martin J, Glennie
Publikováno v:
Cancer cell. 27(1)
Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer treatment but require optimization for maximum clinical impact. Here, we show that, unlike other immunoglobulin isotypes, human IgG2 (h2) imparts FcγR-independ
Autor:
Christopher Anthony, H. T. Claude Chan
Publikováno v:
Journal of General Microbiology. 137:693-704
Membranes of the acidophilic methylotroph Acetobacter methanolicus contained only b- and c-type cytochrome and a CO-binding b-type cytochrome. An azide-sensitive oxidase that oxidizes cytochrome c and ascorbate/TMPD was solubilized from the membrane
Autor:
H T Claude, Chan, David, Hughes, Ruth R, French, Alison L, Tutt, Claire A, Walshe, Jessica L, Teeling, Martin J, Glennie, Mark S, Cragg
Publikováno v:
Cancer research. 63(17)
Rituximab is routinely used for the treatment of neoplasia, although the mechanism of action remains uncertain. In the current study, CD20-induced apoptosis was investigated with a panel of anti-CD20 monoclonal antibodies (mAb) in a wide range of cel